Clinical trial
Temozolomide and Thalidomide in Treating Patients With Brain Metastases…
NCT00072163 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00072163 |
|---|---|
| Title | Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma |
| Official title | A Phase II Study Of Temozolomide And Thalidomide In Patients With Metastatic Melanoma In The Brain |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Melanoma, Stage IV Melanoma, Tumors Metastatic to Brain |
| Intervention type | Drug |
| Interventions | temozolomide, thalidomide |
| Enrollment | 50 |
| Start date | Oct 1, 2003 |
| Primary completion | Sep 1, 2006 |
| First posted | Nov 6, 2003 |
| Last update posted | Jan 17, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: